amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in ZAMBON S.P.A's portfolio.
pharma · Motor fluctuations in advanced Parkinson’s disease · Non Cystic Fibrosis Bronchiectasis
ZAMBON S.P.A
Zambon SpA
ZAMBON S.P.A drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
IT HQ
8 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- IT
- Employees
- 8
- Programs
- 3
- Drugs
- 7
- Patents
- 0
ZAMBON S.P.A pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ZAMBON S.P.A drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
ciclosporin
Sensory organs (S01)Sensory organs (S01) compound in ZAMBON S.P.A's portfolio. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
Development asset linked to ZAMBON S.P.A in public FDA and regional records.
-
levodopa
Nervous system (N04)US regulatory status: approved. Molecular target: D(3) dopamine receptor.
- Target
- D(3) dopamine receptor
- Mechanism
- Dopamine D3 receptor agonist
-
Development asset linked to ZAMBON S.P.A in public FDA and regional records.
-
Development asset linked to ZAMBON S.P.A in public FDA and regional records.